Congo begins trial of Gilead's ($GILD) experimental antiviral for Ebola Bundibugyo

Researchers in the Democratic Republic of Congo have started enrolling participants in a trial testing Gilead Sciences' experimental antiviral obeldesivir as a post-exposure treatment for the ongoing Bundibugyo Ebola outbreak in Congo and Uganda.

Next
Next

FDA approves Vertex's Casgevy for children as young as 2, opening door to thousands more patients